Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
language:"Undetermined"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Severe+Acute+Respiratory+Syndrome%22&type=Subject&filter%5B%5D=language%3A%22Undetermined%22
/vufind/Search/Results?lookfor=%22Severe+Acute+Respiratory+Syndrome%22&type=Subject&filter%5B%5D=language%3A%22Undetermined%22
Search /vufind/Search2/Results?lookfor=%22Severe+Acute+Respiratory+Syndrome%22&type=Subject&filter%5B%5D=language%3A%22Undetermined%22
PubPharm (9)
1
VIDA study : Expanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
CIGB-258 at COVID-19 : Administration of the CIGB-258 peptide in patients with COVID-19 under intensive therapy regimen (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
DALIA Study : Evaluation of the effect and safety of the CIGB-258 peptide in the treatment of seriously or critically ill patients due to COVID-19. (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
VISION Study : Evaluation of the effect and safety terapeutic of Jusvinza in severe patients with COVID-19
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
VIDA study : Expanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
CIGB-258 at COVID-19 : Administration of the CIGB-258 peptide in patients with COVID-19 under intensive therapy regimen (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
DALIA Study : Evaluation of the effect and safety of the CIGB-258 peptide in the treatment of seriously or critically ill patients due to COVID-19. (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
VISION Study : Evaluation of the effect and safety terapeutic of Jusvinza in severe patients with COVID-19
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
Reducing Pandemic Risks at Source : Wildlife, Environment and One Health Foundations in East and South Asia
Erschienen: Washington, DC,
World Bank,
2022
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Sprache: Unbestimmt
Medienart
9
E-Ressourcen
8
Aufsätze
8
E-Artikel
1
Bücher
1
E-Books
Alle anzeigen ...
weniger ...
Zeitschriftentitel
8
WHO International Clinical Trials Registry Plat...
Thema
8
610
8
Study Type: Interventional
4
Recruitment Status: Not yet recruiting
2
Medical Condition: Acute Respiratory Distress b...
2
Medical Condition: COVID-19 respiratory distres...
2
Medical Condition: COVID-19 respiratory distres...
2
Medical Condition: COVID-19 respiratory distres...
2
Recruitment Status: Completed
2
Recruitment Status: Recruiting
1
Emerging Infectious Diseases (eids)
1
Health And Food Security
1
Health Economy
1
Highly Pathogenic Avian Influenzas (hpais)
1
One Health Approach
1
Severe Acute Respiratory Syndrome (sars)
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
8
2023
1
2022
Erscheinungsjahr(e)
Von:
Bis:
Sprache
Unbestimmt
Haven't found what you're looking for?
Wird geladen...